Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533798 | 1.00 | GPR119 (0.35) | GPR119RETHDAC1KRASPARP1 | |
| SCHEMBL26533794 | 1.00 | GPR119 (0.35) | GPR119RETHDAC1KRASPARP1 | |
| SCHEMBL26113915 | 0.95 | KRAS (0.32) | GPR119KRAS | |
| SCHEMBL26532739 | 0.94 | GPR119 (0.34) | GPR119RETHDAC1KRAS | |
| SCHEMBL30587289 | 0.94 | GPR119 (0.34) | GPR119RETHDAC1KRAS | |
| SCHEMBL26114010 | 0.89 | KRAS (0.34) | KRAS | |
| SCHEMBL30776299 | 0.88 | RET (0.33) | GPR119RETHDAC1PARP1 | |
| SCHEMBL26532506 | 0.88 | RET (0.33) | GPR119RETHDAC1PARP1 | |
| SCHEMBL30776384 | 0.87 | KRAS (0.35) | GPR119KRAS | |
| SCHEMBL26533910 | 0.87 | KRAS (0.35) | GPR119KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 617/4885RET 42/4885HDAC1 1452/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | GPR119 617/4885RET 42/4885HDAC1 1452/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 617/4885RET 42/4885HDAC1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.